At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 49 enrolled
Drug / intervention
Omarigliptindrug
Likely dose
Omarigliptin 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function
In Brief
A Phase 1 clinical trial evaluating Omarigliptin for Chronic Renal Insufficiency and Type 2 Diabetes Mellitus. Completed, enrolled 49 participants.
Detailed Summary
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3 mg dose by mouth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartAug 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedAug 2, 2011
Enrollment StartAug 8, 2011
Primary CompletionMar 23, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.9 years ago
Interventions
Omarigliptindrug
Single oral dose of 3 mg (3 x 1-mg capsules)